Decoy Therapeutics Showcases Major Scientific And Corporate Milestones As It Moves Toward Clinical Stage With Its Multi-Antiviral Platform

Decoy Therapeutics, Inc., a biotechnology company developing a new class of antivirals known as Designable Multi-Antivirals (D-MAVs™), shared a series of recent strategic, operational and scientific accomplishments that reflect its increasing momentum and its progress toward becoming a clinical-stage organization. The company also outlined near-term milestones it expects will support continued growth and shareholder value.

In recent months, the company has advanced on multiple fronts, including strengthening its position in the capital markets, progressing its antiviral pipeline and further validating the capabilities of its differentiated D-MAV discovery platform. These combined efforts have set the foundation for several potential value-driving catalysts the company anticipates in the coming period.

Rick Pierce, Chief Executive Officer of Decoy Therapeutics, emphasized that the team is moving quickly and decisively to push its development programs toward the clinic. He noted that the company is making meaningful progress across scientific development, operational execution and strategic positioning, and intends to continue updating stakeholders as the work advances.

Recently, the company achieved several notable milestones that reinforce its long-term growth strategy and enhance its visibility among investors. These include establishing a strategic AI partnership with Quantori and Google Cloud, which is expected to expand computational peptide design capabilities significantly. Decoy was also recognized as a Hello Tomorrow Deep Tech Pioneer, highlighting its innovative technology. In addition, the company entered into a global access commitment with the Bill & Melinda Gates Foundation to support scalable, low-cost manufacturing and global distribution of future antiviral therapies. It also launched an expanded investor relations and social media program intended to improve communication and engagement with the investment community.

Central to the company’s progress is its proprietary IMP³ACT™ platform, which combines AI-driven design, machine learning and rapid peptide-conjugate synthesis to shorten drug development timelines from years to months. Unlike traditional antivirals that act on a single pathogen, Decoy’s D-MAV model is designed to target conserved viral mechanisms, enabling one therapy to work across multiple viruses. This platform allows fast iterative design cycles and significantly accelerates synthesis, transforming what is typically a months-long process into one that can be completed in days. While initially focused on infectious diseases, the platform also holds potential for applications in oncology and other therapeutic areas.

The company is currently advancing a pipeline of broad-acting antiviral candidates aimed at addressing major global health burdens. Its DCOY-COV program, a pan-coronavirus D-MAV, is being developed for high-risk and immunocompromised populations. Preclinical studies have shown broad activity across known human coronaviruses, and the program is supported by non-dilutive funding and global partnerships. A Phase 1 clinical trial is anticipated in 2027. Alongside this, Decoy is progressing DCOY-TRI, a multi-virus respiratory program designed to address influenza, coronavirus and paramyxovirus families, including RSV, using a single therapeutic. Early findings indicate broad coverage across multiple viral families, and the program has the potential to address the majority of viruses responsible for respiratory infections each year. These development efforts position the company within a large and established antiviral market that includes high-value treatments such as Paxlovid.

Decoy is now approaching a particularly important phase in its trajectory, with a clear plan toward clinical development and future value inflection points. The company’s accelerated development strategy, which may incorporate human challenge studies, is designed to shorten the time to clinical proof-of-concept and distinguish its approach from traditional biotechnology timelines.

Key upcoming milestones include advancement toward lead candidate selection, progress on IND-enabling studies, and defining the initial clinical indication and commercial potential for the company’s lead program. Additional milestones will include new scientific presentations and publications, the pursuit of strategic partnerships, and the filing of IND or international equivalents to begin first-in-human studies.

The company operates at the intersection of several important global trends, such as rising demand for broad-spectrum antiviral solutions, increased adoption of AI-enabled drug discovery tools, heightened awareness of pandemic readiness and scalable production, and growing investment in peptide-based medicines. Recent consolidation and acquisitions in the antiviral space have further highlighted the strategic importance of innovative antiviral platforms.

With a differentiated technology platform, a growing pipeline, strong external validation and ongoing operational progress, Decoy Therapeutics is positioning itself as a next-generation leader in antiviral innovation. As it moves closer to clinical development, the company offers exposure to a new therapeutic class, the potential to generate multiple assets from a single platform, a globally relevant market opportunity and several near- and mid-term catalysts.

Rick Pierce reiterated the company’s long-term vision, noting that the future of antiviral medicine will rely on treatments that act across multiple pathogens, can be rapidly developed and are scalable worldwide. He added that Decoy is being built to deliver on that vision.